Eloxx Pharmaceuticals

950 Winter Street
Waltham
Massachusetts
02451
United States

Tel: 1-781-577-5300

Email: info@eloxxpharma.com

Show jobs for this employer

About Eloxx Pharmaceuticals

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.

YEAR FOUNDED: 2013

LEADERSHIP:

Chairman of the Board & CEO: Bob Ward
CMO: Dr. Pedro Huertas
CFO: Gregory Weaver
VP CMC: John van Duzer
Investor Relations: Barbara Ryan
VP Translational Science: Neal Sharpe
 

21 articles with Eloxx Pharmaceuticals